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Background: Recent data indicate that the rs1080985 single nucleotide polymorphism of the 
cytochrome P450 (CYP) 2D6 gene may affect the response to treatment with donepezil in patients 
with Alzheimer’s disease. There is also evidence that the common apolipoprotein E (APOE) 
polymorphism may affect the response to treatment with donepezil in Alzheimer’s disease. We 
investigated the association between response to donepezil and the rs1080985 single nucleotide 
polymorphism, the minor allele (G) of which was previously reported to be associated with a 
poor response to this drug in patients with Alzheimer’s disease. The common APOE polymor-
phism was also assessed for its relevance to the outcome of this treatment.
Methods: Analysis of CYP2D6 and APOE polymorphisms was undertaken in 88 naive 
 Caucasian patients with Alzheimer’s disease. All patients received treatment with donepezil for 
at least 10 months, and the response to treatment was then assessed according to the National 
Institute for Health and Clinical Excellence criteria.
Results: No significant differences were observed in distribution of the CYP2D6 rs1080985 
single nucleotide polymorphism or common APOE polymorphism between responders (68.2%) 
and nonresponders (31.8%) to treatment with donepezil.
Conclusion: Our results suggest that neither the CYP2D6 nor the APOE polymorphism 
influences the response to treatment with donepezil in a Polish population with Alzheimer’s 
disease.
Keywords: Alzheimer’s disease, CYP2D6, APOE, donepezil, pharmacogenetics, single 
nucleotide polymorphism
Introduction
Donepezil is currently used for symptomatic treatment of mild to moderate Alzheimer’s 
disease. Differential response to this treatment has been observed. Interindividual 
genetic variants of genes responsible for drug metabolism (cytochrome P450 [CYP]) 
or genes associated with the pathogenesis of Alzheimer’s disease (apolipoprotein E 
[APOE] common polymorphism) may influence the pharmacokinetic and pharmaco-
dynamic properties of donepezil.1
After oral administration, donepezil undergoes significant first-pass metabolism by 
hepatic microsomal CYP enzymes to several metabolites. The CYP enzymes involved 
in the metabolism of donepezil are CYP3A4 and CYP2D6.2 The CYP2D6 gene (CYP 
family 2, subfamily D, polypeptide 6) is located on chromosome 22q13.1–13.2. This 
locus is highly polymorphic, with a large number of allelic variants identified and 
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 resulting in different degrees of enzymatic activity.3 The 
G allele of the single nucleotide polymorphism, rs1080985 
(C−1584→G), in the promoter region of the CYP2D6 gene, was 
associated with higher gene expression and greater enzymatic 
activity in vivo4,5 and a poor response to treatment with done-
pezil in Italian patients with Alzheimer’s disease.6–8
APOE is a multifunctional protein playing a key role in 
the metabolism of cholesterol and tri glycerides, and in tis-
sue repair and inflammation. The APOE gene is located on 
chromosome 19q13.2, and has three major isoforms encoded 
by the ε2, ε3, and ε4 alleles. The ε4 allele is associated with 
hypercholesterolemia and an increased risk of Alzheimer’s 
disease, while the ε2 allele is associated with the opposite 
effect. The relationship between response to donepezil and 
common APOE polymorphism in patients with Alzheimer’s 
disease has been investigated in several studies, but the results 
are controversial.
The aim of our study was to assess the effect of the 
rs1080985 single nucleotide polymorphism in the promoter 
region of the CYP2D6 gene on the clinical outcome of treat-
ment with donepezil in a Polish population with Alzheimer’s 
disease. The influence of the common APOE polymorphism 
was also assessed for potential relevance to the outcome of 
treatment with a cholinesterase inhibitor.
Patients and methods
Consecutive patients admitted to the Outpatients Memory 
Clinic, Department of Neurology, University Hospital, 
Cracow, Poland, were screened for enrolment in the study. 
Of 361 patients, 245 were excluded because of: refusal to 
enter into the study (n = 16), lack of a reliable caregiver 
(n = 32), and concomitant therapy with drugs metabolized 
extensively by CYP2D6 (anticholinergics, anticonvulsants, 
antidepressants, β-blockers, opioids, antipsychotic drugs, 
n = 197). Finally, 116 patients with Alzheimer’s disease, 
older than 65 years at onset of the disease, and without a 
family history of Alzheimer’s disease were included. Onset 
of the disease was defined as the age at which memory loss 
or change in behavior were first noted. The diagnosis of prob-
able Alzheimer’s disease was made according to the National 
Institute for Neurological and Communicative Disorders and 
Stroke and the Alzheimer’s Disease and Related Disorders 
Association criteria,9 with a mild to moderate degree of dis-
ease severity. The evaluation included medical, neurologic, 
and neuropsychologic examinations, interviews with a close 
informant, laboratory testing, and computed tomography/
magnetic resonance imaging. Cognitive status was evaluated 
by neuropsychologic examination.10 Patients included in the 
study were treated with donepezil 5 mg/day for one month, 
after which the dose was increased to 10 mg a day. Follow-up 
visits were scheduled at months 6 and 9 of treatment with 
donepezil 10 mg. The response to donepezil was defined 
according to the criteria recommended by the National 
Institute for Health and Clinical Excellence.11 A responder 
was defined as a patient who showed improvement or no 
deterioration in cognition (evaluated by Mini Mental State 
Examination [MMSE] and the Clock Drawing Test [CDT]), 
and showed evidence of global improvement on behavioral 
or functional assessment (instrumental activities of daily 
living, IADL). All patients with Alzheimer’s disease were 
Caucasian and of Eastern European descent. All participants 
gave their informed consent and the study was approved by 
the local ethics committee.
DNA analyses
Real-time polymerase chain reaction was performed using 
the protocol provided to assess rs1080985 single nucleotide 
polymorphism of the CYP2D6 gene. To determine the APOE 
genotype (APOE ε2, APOE ε3, APOE ε4 alleles), we geno-
typed two single nucleotide polymorphisms (rs429358 and 
rs7412, National Center for Biotechnology Information) 
using the TaqMan assay (Applied Biosystems, Foster City, 
CA, USA).
Statistical analysis
Demographic data between the groups were compared by 
χ2 (gender) or t-test (age). The genotype frequencies were 
compared between responders and nonresponders using the 
χ2 test. For abnormally distributed variables, differences 
between the groups were tested using the Mann–Whitney 
U-test. Hardy–Weinberg equilibrium was verified for all 
tested populations (SAS Genetics version 9.1, SAS Insti-
tute Inc, Cary, NC, USA). Adjusted odds ratios (OR) with 
95% confidence intervals (CI) were estimated by logistic 
regression, controlling for APOE carrier status, gender, age, 
and MMSE at baseline. The level of significance was set at 
P , 0.05.
We hypothesized that response to the drug would be 
able to be detected in two thirds of the 116 patients who 
entered the study, while the remaining one third of patients 
would show no drug response, according to response rates 
from previously published studies.2,6,12,13 We also assumed 
the presence of an alternative genotype (GG or GC) in 40% 
of subjects versus the wild-type genotype CC present in 
60% of patients. Under these assumptions, the study has a 
power of 80% to detect an association between alternative 
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CYP genotypes and response to the drug in patients with 
Alzheimer’s disease at the level of significance of 0.05 if 
the OR of association is lower than 0.23 or higher than 3.7.
Calculated post hoc, the power in this study of 88 patients 
who actually completed follow-up (response to the drug 
detected in 68% of subjects and alternative genotype present 
in 39% of subjects) was 7.2% for an OR of 0.8 and 5.45% 
for an OR of 0.9 (lack of response to the drug detected in 
32% of nonresponders and alternative genotypes present in 
47% of responders).
Results
Of 116 consecutive patients (mean age 72.72 ± 7.04 years, 
78 females [67.24%]), 28 (mean age 73.61 ± 7.24 years, 
18 female [64.3%]) were excluded because they did not 
attend the follow-up visit at 7 or 10 months from initiation 
of treatment. Analysis of the rs1080985 single nucleotide 
polymorphism showed that 67 patients were CC homozy-
gotes (57.76%), 38 were CG heterozygotes (33.45%), and 
11 were GG homozygotes (9.48%). No differences were 
found between these observed frequencies and the expected 
Hardy–Weinberg frequencies for this locus (P = 0.12).
Analysis of the APOE polymorphism showed that 
nine patients were ε2/ε3 heterozygotes (7.76%), 54 were 
ε3/ε3 homozygotes (46.55%), one was a ε2/ε4 heterozy-
gote (0.86%), 43 were ε3/ε4 heterozygotes (37.07%), and 
nine were ε4/ε4 homozygotes (7.76%). No differences were 
found between these observed frequencies and the expected 
Hardy–Weinberg frequencies for this locus (P = 0.57). The 
patients lost to follow-up did not differ significantly in age 
at onset of the disease, sex, MMSE, CDT, and IADL score, 
or CYP2D6 polymorphism when compared with the rest of 
the group (data not shown).
During follow-up, three patients complained of nausea 
and vomiting when the donepezil dose was increased to 
10 mg; however, when the dose was reduced and after 2 
weeks it was again increased up to 10 mg, these patients 
were still eligible for assessment after 6 and 9 months. Of 
the 88 patients who were followed up, 60 were identified as 
responders. There was no significant difference with regard to 
age, sex, or scores on the MMSE, CDT, and IADL between 
responders and nonresponders. The characteristics of the 
patients at baseline are summarized in Table 1.
The CYP2D6 and APOE polymorphisms were in Hardy–
Weinberg equilibrium (P = 0.12, and P = 0.57, respectively). 
No differences were found between the rs1080985 genotype 
distribution in the two groups (P = 0.79; Fisher’s Exact test, 
Table 1). Logistic regression analysis adjusted for age, sex, 
MMSE score at baseline, and APOE polymorphism showed 
no association between CG heterozygotes (P = 0.70, OR 0.80; 
95% CI 0.30–2.28) or GG homozygotes (P = 0.90, OR 0.90; 
95% CI 0.15–5.40) and response to treatment.
Table 1 Demographic and clinical characteristics of patients with Alzheimer’s disease who completed the follow-up visit
Characteristics Responders (n = 60) Nonresponders (n = 28) P-value
Age at onset of ADa (years) 72.23 ± 7.40 72.86 ± 6.10 0.27
Age at baselinea (years) 74.36 ± 7.44 75.14 ± 5.8 0.16
Women, n (%) 39 (65) 21 (75) 0.35
iaDl scoreb 12 (9–12) 14 (11.5–17.5) 0.06
MMse scoreb 23 (14–29) 22 (17–25) 0.20
cDT scoreb 8 (5–10) 5.5 (3–9) 0.06
APOE polymorphism
 2/3, n (%) 4 (6.66) 3 (10.71) cOR 0.83, 95% CI 0.33–2.01, P = 0.66
 3/3, n (%) 29 (48.34) 11 (39.28) dOR 0.69, 95% CI 0.28–1.72, P = 0.43
 2/4, n (%) 1 (7.67) eOR 0.73, 95% CI 0.28–1.89, P = 0.52
 3/4, n (%) 21 (35) 13 (4.6) fOR 0.63, 95% CI 0.13–3.10, P = 0.42
 4/4, n (%) 5 (8.34) 1 (3.57)
rs1080985 SNP
 GG, n (%) 6 (10%) 2 (7.14%) OR 1.44, 95% CI 0.26–7.65, P = 0.67 
(dominant g allele)
 CG, n (%) 22 (36.7%) 9 (32.14%) OR 0.61, 95% CI 0.23–1.57, P = 0.51 
(dominant c allele)
 CC, n (%) 32 (53.3%) 17 (60.7%) OR 0.76, 95% CI 0.38–1.60, P = 0.50 
(additive model)
Notes: aMean ± standard deviation; bmean, interquartile range; cgenotype with ε4 allele versus other genotype; dgenotype with ε4 or ε2 allele or versus ε3ε3 genotype; 
egenotype with ε4 allele versus ε3ε3 genotype; fgenotype with ε2 allele versus ε3ε3 genotype; single nucleotide polymorphism.
Abbreviations: AD, Alzheimer’s disease; CDT, Clock Drawing Test; CI, confidence interval; IADL, instrumental activities of daily living; SNP, single nucleotide polymorphism; 
OR, odds ratio; MMSE, Mini Mental State Examination; APOE, apolipoprotein E.
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Discussion
The variable therapeutic response to donepezil observed in 
patients with Alzheimer’s disease may be caused by differ-
ences in the efficacy of cholinesterase inhibitors resulting 
from individual genetic variation in genes that influence 
the pharmacokinetic and pharmacodynamic properties of 
this drug. Identification of specific genetic polymorphisms 
associated with a good response to treatment with donepezil 
would allow an individually designed approach to therapy 
for patients with Alzheimer’s disease.
To date, over 20 studies have investigated the relation-
ship between responsiveness to cholinergic therapy and 
common APOE polymorphism. In general, their results can 
be divided into two groups, ie, those showing no effect of 
APOE status on response to treatment and those showing that 
patients with the ε4 allele had a better response to treatment 
than others.13–18 Only two studies showed a better response 
to treatment in patients with Alzheimer’s disease not carry-
ing the ε4 allele of the APOE gene.19,20 The studies showing 
response to treatment had a longer observational period 
(12–36 months) than those not finding such an association 
(3–12 months).13,17,18
Two studies that analyzed the interaction between APOE 
status and rs1080985 did not find a direct interaction between 
APOE and CYP2D6 polymorphisms.7,8 In one of these stud-
ies, a marginal significance for frequency of the APOE ε4 
and rs1080985 G allele was found, but an independent effect 
of APOE ε4 on response to donepezil was not found.8 In our 
study, APOE ε4 was not significantly associated with the 
therapeutic response to donepezil. None of the three stud-
ies supported the hypothesis of a direct interaction between 
APOE and CYP2D6 polymorphisms on response to treatment 
with donepezil.
Factors influencing the response to donepezil were 
evaluated in a few studies and yielded inconsistent results. 
Darreh-Shori et al showed better therapeutic results after 
2 years of treatment, in patients who had an increased 
donepezil concentration in blood and cerebrospinal fluid.21 
However, a study by Yuan-Han et al showed that patients 
treated with donepezil who did not respond to the drug after 
6 months had a higher plasma concentration of donepezil. 
To explain these inconsistent results, a therapeutic win-
dow in the treatment of Alzheimer’s disease by donepezil 
was postulated; an increased concentration of the drug 
may not improve  cognitive and global function, but may 
induce clinical tolerance that may lead to a poor therapeutic 
response.13,22
The plasma concentration of donepezil is dependent 
on CYP2D6 polymorphism. A number of allelic variants 
causing either absent, decreased, or increased enzymatic 
activity have been described,3 allowing for categorization 
of the populations into three groups, ie, poor metaboliz-
ers, extensive metabolizers, and ultrarapid metabolizers. 
The efficacy of donepezil after 3 months of treatment in 
42 Italian patients with Alzheimer’s disease23 and in another 
Italian population of 57 patients with Alzheimer’s disease 
after 6 months6 showed that poor metabolizers are better 
responders. However, a study by Chianella et al24 evaluat-
ing 92 patients after one year of treatment with donepezil 
reported a general tendency towards a higher frequency of 
faster metabolizers in responders.
The phenotypic outcome of rs1080858 (C−1584→G) 
in the promoter region of the CYP2D6 gene remains 
controversial.4,5 The influence of rs1080985 on response 
to treatment with donepezil was assessed in three Italian 
studies.6–8 The frequency of the G allele was higher in 
nonresponders than in responders, and the presence of the 
G allele was associated with a poor response to treatment 
with donepezil; however, the effect size of the modulation 
of donepezil response was small to moderate. We were not 
able to replicate these results in our study. We did not find 
an association between the rs1080985 single nucleotide 
polymorphism of the CYP2D6 gene and response to treat-
ment in a Polish population. The G allele was found more 
often in responders than in nonresponders, but the difference 
was not significant.
Although data regarding the CYP2D6 polymorphism 
are inconclusive, they do not rule out the role of rs1080985 
as a marker of response to therapy. It was suggested that 
another genetic variant of CYP2D6 may be in linkage dis-
equilibrium with rs1080985 and influence the phenotypic 
effect of this polymorphism.23 Further, other as yet unknown 
factors beyond the concentration of donepezil and CYP2D6 
polymorphism influencing poor therapeutic responses need 
to be clarified.
Genetic replication studies are important, especially in 
different ethnic groups, to confirm the first observation usu-
ally in small populations. So far, the results of published stud-
ies encourage continued evaluation of the role of rs1080985 
polymorphism in response to treatment with donepezil in 
different populations.
Disclosure
The authors report no conflicts of interest in this work.
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